Pink SheetThe novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp
ScripCG Oncology believes that the Phase III data for its oncolytic immunotherapy for bladder cancer show that cretostimogene grenadenorepvec can spare patients bladder surgery, and analysts said the data
ScripJohnson & Johnson 's 2019 acquisition of privately held TARIS Biomedical LLC for an undisclosed sum is looking like a canny move after new data from early trials of its lead product, TAR-200, sugges
ScripThe looming passage of the BIOSECURE Act in the US appears to be changing the landscape of the global contract development and manufacturing organization (CDMO) industry. Amid the absence of major Chi